Equities Analysts Issue Forecasts for LRMR FY2027 Earnings

Key Points

• Wedbush has revised its FY2027 earnings per share (EPS) estimate for Larimar Therapeutics to ($1.43), down from ($1.21), maintaining an "Outperform" rating with a $11.00 price target.
• The stock currently has an average rating of "Buy" from nine research analysts, with a consensus target price of $17.43.
• Director James E. Flynn significantly increased his stake in the company by purchasing 9,375,000 shares for a total value of $30 million at an average price of $3.20 per share.

Larimar Therapeutics, Inc. (NASDAQ:LRMR - Free Report) - Wedbush cut their FY2027 earnings per share (EPS) estimates for shares of Larimar Therapeutics in a report issued on Tuesday, September 30th. Wedbush analyst L. Chico now expects that the company will post earnings per share of ($1.43) for the year, down from their previous estimate of ($1.21). Wedbush has a "Outperform" rating and a $11.00 price objective on the stock. The consensus estimate for Larimar Therapeutics' current full-year earnings is ($1.15) per share. Wedbush also issued estimates for Larimar Therapeutics' FY2028 earnings at ($0.49) EPS and FY2029 earnings at $0.83 EPS.

Larimar Therapeutics (NASDAQ:LRMR - Get Free Report) last posted its quarterly earnings results on Thursday, August 14th. The company reported ($0.41) earnings per share for the quarter, topping the consensus estimate of ($0.47) by $0.06.

LRMR has been the topic of a number of other research reports. Guggenheim reaffirmed a "buy" rating and set a $26.00 price target on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Citigroup restated a "buy" rating on shares of Larimar Therapeutics in a report on Tuesday, June 24th. Robert W. Baird cut their target price on shares of Larimar Therapeutics from $10.00 to $7.00 and set an "outperform" rating for the company in a research report on Tuesday. Finally, JMP Securities lowered their price target on Larimar Therapeutics from $22.00 to $18.00 and set a "market outperform" rating on the stock in a report on Friday, August 15th. Nine research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has an average rating of "Buy" and a consensus target price of $17.43.

Larimar Therapeutics Stock Performance

NASDAQ LRMR opened at $4.15 on Thursday. Larimar Therapeutics has a one year low of $1.61 and a one year high of $9.50. The stock has a 50-day moving average of $3.90 and a 200 day moving average of $2.97. The company has a market capitalization of $343.54 million, a price-to-earnings ratio of -2.66 and a beta of 1.00.

Hedge Funds Weigh In On Larimar Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of America Corp DE boosted its stake in Larimar Therapeutics by 8.1% in the 4th quarter. Bank of America Corp DE now owns 53,190 shares of the company's stock worth $206,000 after purchasing an additional 3,980 shares during the period. Velan Capital Investment Management LP lifted its holdings in shares of Larimar Therapeutics by 17.9% in the second quarter. Velan Capital Investment Management LP now owns 33,000 shares of the company's stock worth $95,000 after buying an additional 5,000 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Larimar Therapeutics by 7.8% during the second quarter. American Century Companies Inc. now owns 69,285 shares of the company's stock worth $200,000 after acquiring an additional 5,001 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Larimar Therapeutics during the fourth quarter worth $25,000. Finally, Rhumbline Advisers grew its stake in Larimar Therapeutics by 15.7% during the first quarter. Rhumbline Advisers now owns 65,018 shares of the company's stock valued at $140,000 after acquiring an additional 8,818 shares in the last quarter. 91.92% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Larimar Therapeutics

In other Larimar Therapeutics news, Director James E. Flynn acquired 9,375,000 shares of the business's stock in a transaction dated Thursday, July 31st. The stock was purchased at an average price of $3.20 per share, with a total value of $30,000,000.00. Following the transaction, the director directly owned 9,538,945 shares in the company, valued at approximately $30,524,624. The trade was a 5,718.38% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 4.50% of the stock is owned by corporate insiders.

About Larimar Therapeutics

Larimar Therapeutics, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 2 OLE clinical trial for the treatment of Friedreich's ataxia, a rare, progressive and fatal genetic disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.